The BRAF-inhibitor PLX4720 inhibits CXCL8 secretion in BRAFV600E mutated and normal thyroid cells: a further anti-cancer effect of BRAF-inhibitors
暂无分享,去创建一个
M. Rotondi | L. Chiovato | L. Persani | M. Muzza | M. Denegri | F. Latrofa | F. Coperchini | L. Croce | O. Awwad | S. T. Ngnitejeu | V. Capelli
[1] M. Rotondi,et al. Role of Chemokines in Thyroid Cancer Microenvironment: Is CXCL8 the Main Player? , 2018, Front. Endocrinol..
[2] R. Franco,et al. Interleukin‐8, but Not the Related Chemokine CXCL1, Sustains an Autocrine Circuit Necessary for the Properties and Functions of Thyroid Cancer Stem Cells , 2017, Stem cells.
[3] A. Balduini,et al. Effect of Interferon-γ on the Basal and the TNFα-Stimulated Secretion of CXCL8 in Thyroid Cancer Cell Lines Bearing Either the RET/PTC Rearrangement Or the BRAF V600e Mutation , 2016, Mediators of inflammation.
[4] Duane H. Hamilton,et al. The IL-8/IL-8R Axis: A Double Agent in Tumor Immune Resistance , 2016, Vaccines.
[5] M. Rotondi,et al. Normal human thyroid cells, BCPAP, and TPC-1 thyroid tumor cell lines display different profile in both basal and TNF-α-induced CXCL8 secretion , 2016, Endocrine.
[6] A. Balduini,et al. TNF-α increases the membrane expression of the chemokine receptor CCR6 in thyroid tumor cells, but not in normal thyrocytes: potential role in the metastatic spread of thyroid cancer , 2016, Tumor Biology.
[7] R. Franco,et al. Mast cells induce epithelial-to-mesenchymal transition and stem cell features in human thyroid cancer cells through an IL-8–Akt–Slug pathway , 2015, Oncogene.
[8] M. Rotondi,et al. Metformin reverts the secretion of CXCL8 induced by TNF-α in primary cultures of human thyroid cells: an additional indirect anti-tumor effect of the drug. , 2015, The Journal of clinical endocrinology and metabolism.
[9] Weiqing Wang,et al. Tumor-associated macrophages promote the metastatic potential of thyroid papillary cancer by releasing CXCL8. , 2014, Carcinogenesis.
[10] M. A. Marcello,et al. The role of the inflammatory microenvironment in thyroid carcinogenesis. , 2014, Endocrine-related cancer.
[11] Huang,et al. Tumor-associated macrophages promote the metastatic potential of thyroid papillary cancer by releasing CXCL8. , 2014, Carcinogenesis.
[12] M. Rotondi,et al. CXCL8 in thyroid disease: from basic notions to potential applications in clinical practice. , 2013, Cytokine & growth factor reviews.
[13] M. Rotondi,et al. Type I and type II interferons inhibit both basal and tumor necrosis factor-α-induced CXCL8 secretion in primary cultures of human thyrocytes. , 2013, Journal of interferon & cytokine research : the official journal of the International Society for Interferon and Cytokine Research.
[14] A. Viale,et al. Relief of Feedback Inhibition of Her3 Transcription by Raf and Mek Inhibitors Attenuates Their Antitumor Effects in Braf -mutant Thyroid Carcinomas Human Oncology and Pathogenesis Program, Pathology, And , 2022 .
[15] P. Ladenson,et al. Association between BRAF V600E mutation and mortality in patients with papillary thyroid cancer. , 2013, JAMA.
[16] A. Balduini,et al. Discoidin Domain Receptor 1 Protein Is a Novel Modulator of Megakaryocyte-Collagen Interactions* , 2013, The Journal of Biological Chemistry.
[17] M. Rotondi,et al. Interferon-γ and tumor necrosis factor-α sustain secretion of specific CXC chemokines in human thyrocytes: a first step toward a differentiation between autoimmune and tumor-related inflammation? , 2013, The Journal of clinical endocrinology and metabolism.
[18] R. Melillo,et al. Inflammation in thyroid oncogenesis. , 2012, American journal of cancer research.
[19] Kinam Park,et al. Targeted drug delivery to tumors: myths, reality and possibility. , 2011, Journal of controlled release : official journal of the Controlled Release Society.
[20] Marianne D. Castillo,et al. IL-8 signaling plays a critical role in the epithelial-mesenchymal transition of human carcinoma cells. , 2011, Cancer research.
[21] C. Nucera,et al. BRAF(V600E) and microenvironment in thyroid cancer: a functional link to drive cancer progression. , 2011, Cancer research.
[22] A. Fischer,et al. Targeting BRAFV600E with PLX4720 Displays Potent Antimigratory and Anti-invasive Activity in Preclinical Models of Human Thyroid Cancer , 2011, The oncologist.
[23] T. Giordano,et al. B-RafV600E and thrombospondin-1 promote thyroid cancer progression , 2010, Proceedings of the National Academy of Sciences.
[24] B. Haugen,et al. Tumor-associated lymphocytes and increased FoxP3+ regulatory T cell frequency correlate with more aggressive papillary thyroid cancer. , 2010, The Journal of clinical endocrinology and metabolism.
[25] M. Santoro,et al. Cytostatic activity of adenosine triphosphate-competitive kinase inhibitors in BRAF mutant thyroid carcinoma cells. , 2009, The Journal of clinical endocrinology and metabolism.
[26] C. Nucera,et al. A novel orthotopic mouse model of human anaplastic thyroid carcinoma. , 2009, Thyroid : official journal of the American Thyroid Association.
[27] M. McMahon,et al. Oncogenic BRAFV600E inhibits BIM expression to promote melanoma cell survival , 2008, Pigment cell & melanoma research.
[28] A. Pinchera,et al. BRAF(V600E) mutation and outcome of patients with papillary thyroid carcinoma: a 15-year median follow-up study. , 2008, The Journal of clinical endocrinology and metabolism.
[29] Jianmei Wei,et al. A novel B-RAF inhibitor blocks interleukin-8 (IL-8) synthesis in human melanoma xenografts, revealing IL-8 as a potential pharmacodynamic biomarker , 2008, Molecular Cancer Therapeutics.
[30] M. Loda,et al. BRAF(V600E) mutation and the biology of papillary thyroid cancer. , 2008, Endocrine-related cancer.
[31] Kam Y. J. Zhang,et al. Discovery of a selective inhibitor of oncogenic B-Raf kinase with potent antimelanoma activity , 2008, Proceedings of the National Academy of Sciences.
[32] D. Peeper,et al. BRAFE600 in benign and malignant human tumours , 2008, Oncogene.
[33] S. Asa,et al. Enhanced B-Raf protein expression is independent of V600E mutant status in thyroid carcinomas. , 2007, Human pathology.
[34] M. Xing,et al. BRAF mutation in papillary thyroid cancer: pathogenic role, molecular bases, and clinical implications. , 2007, Endocrine reviews.
[35] M. Xing,et al. BRAF V600E maintains proliferation, transformation, and tumorigenicity of BRAF-mutant papillary thyroid cancer cells. , 2007, The Journal of clinical endocrinology and metabolism.
[36] P. Beck‐Peccoz,et al. BRAF mutations in an Italian cohort of thyroid cancers , 2004, Clinical endocrinology.
[37] T. Kawabe,et al. Functional analysis of mutations within the kinase activation segment of B-Raf in human colorectal tumors. , 2003, Cancer research.
[38] G. Francis,et al. Papillary thyroid carcinomas from young adults and children contain a mixture of lymphocytes. , 2003, The Journal of clinical endocrinology and metabolism.
[39] A. Nicholson,et al. Mutations of the BRAF gene in human cancer , 2002, Nature.
[40] Shinichiro,et al. Carcinoma , 1906, The Hospital.